Dr. Nikolai Podoltsev presents @eaonc E1910 Ph III trial of the addition of Blinatumomab to consolidation therapy for older, newly diagnosed patients with BCR::ABL1 negative B-Lineage Acute Lymphoblastic Leukemia #ALL#ASH24 with Selina Loger, MD @PennCancer & @MRLitzow https://t.co/up0lzs680l
Had an amazing time at #ASH2024 meeting friends, attending great talks and finally getting the great news of passing my Hematology ABIM while enjoying this great view of SD.
Dr Luca Lanino @YaleCancer@HumanitasMilano presenting an excellent project that developed a molecular classification & a new, independently validated, risk stratification tool that outperformed all the other available for #CMML in collaboration with @genomed4all@ic_MDS
.@KunalPotnis reveals that at the current pricing, eltrombopag plus traditional immunosuppressive therapy is unlikely to be a cost-effective treatment for adults with severe aplastic anemia in the US. #ASH24@GeorgeGoshuaMD@YaleHematology@SmilowCancer https://t.co/ztySpPoq7K
Dr @JMStempel fantastically presented our investigator-initiated randomized phase 2 trial of aza-ven +/- Pembro in older #AMLsm#ASH24 which was unfortunately -ve but showed importance of using ELN2024 for risk stratification & feasibility of central MRD in primary endpoint #IMG
It might take us a second to coordinate getting a group picture, but it's because we just like each other. And we certainly love our first year fellows class! It was a joy learning about each of you at the Heme-Onc Fellows Welcome Party. You already make our family richer. 💙